Saol Therapeutics Resubmits the New Drug Application for SL1009 (DCA) for the Treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD), an Ultra-Rare Disease
Existing data supports direct path to resubmission following constructive FDA engagement ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, July 7, 2026 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced the resubmission of its New Drug...
Existing data supports direct path to resubmission following constructive FDA engagement ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, July 7, 2026 /PRNewswire/ -- Saol Therapeutics, a privately held, clinical-stage pharmaceutical company, today announced the resubmission of its New Drug...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.